Olanzapine induced neuroleptic malignant syndrome

Indian Journal of Pharmacology

Volumn 45, Issue 1, 2013, Pages 98-99

  Patra, Bichitra Nanda ^a   Khandelwal, Sudhir K ^b   Sood, Mamta ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bipolar affective disorder; Neuroleptic malignant syndrome; olanzapine

Indexed keywords

ARIPIPRAZOLE; BROMOCRIPTINE; LEVODOPA; LORAZEPAM; OLANZAPINE; SERTRALINE;

ADULT; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LUNG TUBERCULOSIS; MALE; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREMOR;

BIPOLAR AFFECTIVE DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; OLANZAPINE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 84874878183     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.106448     Document Type: Article

References (4)

1. Khaldi S, Kornreich C, Choubani Z, Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: A brief review. Encephale 2008;34:618-24.
2. Sarkar P, Natarajan C, Gode N. Prevalence of Neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J Psychiatry 2009;51:202-5. Available from: http://who-umc.org/Graphics/24734.pdf. [Last accessed on 2012 May 11].
3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
4. Hartwig SC, Siegel J, Schneider PJ. Preventability and Severity Assessment in Reporting Adverse Drug reactions. Am J Hosp Pharm 1992;49:2229-31.